Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $110,653.92 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.36, for a total value of $110,653.92. Following the transaction, the insider now directly owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Aura Biosciences Stock Down 1.9 %

Shares of AURA stock opened at $8.75 on Thursday. The stock has a 50-day moving average price of $9.84 and a 200 day moving average price of $8.56. The firm has a market cap of $437.07 million, a price-to-earnings ratio of -5.21 and a beta of 0.33. Aura Biosciences, Inc. has a 12 month low of $6.63 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. Sell-side analysts predict that Aura Biosciences, Inc. will post -1.69 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AURA. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. BTIG Research raised their target price on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. JMP Securities lifted their price objective on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, September 13th. Finally, Scotiabank lifted their price objective on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $23.00.

Hedge Funds Weigh In On Aura Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. bought a new position in shares of Aura Biosciences during the 2nd quarter valued at about $119,000. American International Group Inc. lifted its stake in Aura Biosciences by 27.4% in the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares in the last quarter. Virtu Financial LLC bought a new stake in Aura Biosciences in the 1st quarter valued at approximately $144,000. SG Americas Securities LLC bought a new stake in Aura Biosciences in the 3rd quarter valued at approximately $169,000. Finally, Rhumbline Advisers lifted its stake in Aura Biosciences by 39.6% in the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after acquiring an additional 18,011 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.